NICE recommends Xofigo (radium-223) for prostate cancer
19 November 2015 | By Victoria White
NICE’s FAD coincides with a period of great uncertainty with the Cancer Drugs Fund deliberating again whether to remove radium-223 from the list...
List view / Grid view
19 November 2015 | By Victoria White
NICE’s FAD coincides with a period of great uncertainty with the Cancer Drugs Fund deliberating again whether to remove radium-223 from the list...
13 November 2015 | By Victoria White
GBI Research says the rise will be driven primarily by growth in disease prevalence due to an aging global population...
29 October 2015 | By Victoria White
The trial is a milestone in cancer treatment as the first to show the benefits of ‘precision medicine’ in prostate cancer...
The ability of mutated cells to give rise to pathological cancer relies upon the capability of these cells to evade immune recognition, suppress immune activity, and persist in a chronically inflamed environment. Tremendous growth in the understanding of these complex processes is beginning to generate breakthroughs in the treatment of…
3 August 2015 | By Victoria White
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers have found...
17 June 2015 | By Victoria White
The pancreatic cancer treatment pipeline is dominated by early-stage development, meaning many therapies are unlikely to reach the market in the near future...
8 June 2015 | By Victoria White
The National Institute for Health and Care Excellence (NICE) has launched public consultations on draft recommendations for two prostate cancer drugs...
1 June 2015 | By Victoria White
A new study compared the effectiveness of cabazitaxel alone versus cabazitaxel combined with carboplatin in patients with mCRPC...
Phase I study evaluating safety and tolerability of VXM01 in pancreatic cancer...